MAFD8
MCID: MJR022
MIFTS: 39

Major Affective Disorder 8 (MAFD8)

Categories: Genetic diseases, Mental diseases

Aliases & Classifications for Major Affective Disorder 8

MalaCards integrated aliases for Major Affective Disorder 8:

Name: Major Affective Disorder 8 57 13 72
Major Affective Disorder-8, Susceptibility to 57
Bipolar Affective Disorder 57
Major Affective Disorder-8 57
Bipolar Disorder 72
Mafd8 57

Classifications:



External Ids:

OMIM 57 612357
MedGen 42 C2700439
UMLS 72 C0005586 C2700439

Summaries for Major Affective Disorder 8

MalaCards based summary : Major Affective Disorder 8, also known as major affective disorder-8, susceptibility to, is related to major affective disorder 1 and bipolar disorder. An important gene associated with Major Affective Disorder 8 is MAFD8 (Major Affective Disorder-8, Susceptibility To). The drugs Paroxetine and Reboxetine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes.

More information from OMIM: 612357

Related Diseases for Major Affective Disorder 8

Diseases in the Major Affective Disorder 1 family:

Major Affective Disorder 2 Major Affective Disorder 3
Major Affective Disorder 4 Major Affective Disorder 5
Major Affective Disorder 6 Major Affective Disorder 8
Major Affective Disorder 7 Major Affective Disorder 9

Diseases related to Major Affective Disorder 8 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 187)
# Related Disease Score Top Affiliating Genes
1 major affective disorder 1 12.5
2 bipolar disorder 12.3
3 major affective disorder 5 12.0
4 major affective disorder 6 12.0
5 major affective disorder 2 12.0
6 major affective disorder 9 11.9
7 major affective disorder 3 11.6
8 major affective disorder 4 11.6
9 major affective disorder 7 11.6
10 mood disorder 10.7
11 endogenous depression 10.5
12 schizophrenia 10.5
13 depression 10.5
14 mental depression 10.5
15 bipolar i disorder 10.4
16 major depressive disorder 10.4
17 personality disorder 10.3
18 psychotic disorder 10.3
19 schizoaffective disorder 10.3
20 alcohol dependence 10.3
21 tardive dyskinesia 10.3
22 obsessive-compulsive disorder 10.3
23 hypothyroidism 10.2
24 substance abuse 10.2
25 cyclothymic disorder 10.2
26 huntington disease 10.1
27 attention deficit-hyperactivity disorder 10.1
28 mental health wellness 1 10.1
29 mental health wellness 2 10.1
30 severe combined immunodeficiency 10.1
31 multiple sclerosis 10.1
32 autism 10.1
33 thalassemia 10.1
34 hydrocephalus 10.1
35 borderline personality disorder 10.1
36 avoidant personality disorder 10.1
37 adenoma 10.1
38 congenital hydrocephalus 10.1
39 head injury 10.1
40 schizophrenia 1 10.0
41 frontotemporal dementia 10.0
42 anxiety 10.0
43 alacrima, achalasia, and mental retardation syndrome 10.0
44 exanthem 10.0
45 physical disorder 10.0
46 dementia 10.0
47 alcohol use disorder 10.0
48 movement disease 10.0
49 panic disorder 10.0
50 hyperthyroidism 10.0

Graphical network of the top 20 diseases related to Major Affective Disorder 8:



Diseases related to Major Affective Disorder 8

Symptoms & Phenotypes for Major Affective Disorder 8

Clinical features from OMIM:

612357

Drugs & Therapeutics for Major Affective Disorder 8

Drugs for Major Affective Disorder 8 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 457)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
2
Reboxetine Approved, Experimental Phase 4 98769-81-4, 71620-89-8 123628 65856
3
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
4
Galantamine Approved Phase 4 357-70-0 9651
5
Ropinirole Approved, Investigational Phase 4 91374-21-9, 91374-20-8 5095 497540
6
Memantine Approved, Investigational Phase 4 19982-08-2 4054
7
Topiramate Approved Phase 4 97240-79-4 5284627
8
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
9
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
10
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
11
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
12
Levetiracetam Approved, Investigational Phase 4 102767-28-2 441341
13
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
14
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
15
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
16
Norepinephrine Approved Phase 4 51-41-2 439260
17
Sertraline Approved Phase 4 79617-96-2 68617
18
Nortriptyline Approved Phase 4 72-69-5 4543
19
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
20
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
21
Mirtazapine Approved Phase 4 61337-67-5, 85650-52-8 4205
22
Histamine Approved, Investigational Phase 4 51-45-6 774
23
Ondansetron Approved Phase 4 99614-02-5 4595
24
Iloperidone Approved Phase 4 133454-47-4 71360
25
Brexpiprazole Approved, Investigational Phase 4 913611-97-9 11978813
26
Methohexital Approved Phase 4 151-83-7 9034
27
Dipyridamole Approved Phase 4 58-32-2 3108
28
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
29
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
30
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
31
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
32
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
33
Metformin Approved Phase 4 657-24-9 4091 14219
34
Racepinephrine Approved Phase 4 329-65-7 838
35
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
36
Simvastatin Approved Phase 4 79902-63-9 54454
37
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
38
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
39
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
40
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
41
Acetaminophen Approved Phase 4 103-90-2 1983
42
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
43
Losartan Approved Phase 4 114798-26-4 3961
44
Loxapine Approved Phase 4 1977-10-2 3964
45
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
46
Eleuthero Approved, Experimental Phase 4
47
Oxcarbazepine Approved Phase 4 28721-07-5 34312
48
Clozapine Approved Phase 4 5786-21-0 2818
49
Nicotine Approved Phase 4 54-11-5 942 89594
50
Promethazine Approved, Investigational Phase 4 60-87-7 4927

Interventional clinical trials:

(show top 50) (show all 1439)
# Name Status NCT ID Phase Drugs
1 An Open Label, Multicenter, Single Arm, 4-Week Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
2 Effects of N-Acetyl-Cysteine on Oxidative Stress Biomarkers in Bipolar Patients With and Without Tobacco Use Disorder Unknown status NCT02252341 Phase 4
3 Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder Unknown status NCT00608075 Phase 4 lithium;Lithium
4 Exploring Alterations of Central Autonomic Modulation in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
5 A Randomized, Double-blind, Placebo-controlled Study of Quetiapine SR and Divalproex Sodium ER on Anxiety in Bipolar Disorder With at Least Moderately Severe Current Anxiety and Lifetime Panic or Generalized Anxiety Disorder. Unknown status NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
6 Assessing the Efficacy of Left Repetitive Transcranial Magnetic Stimulation (rTMS) as an Adjunctive Treatment to Mood Stabilizers for the Treatment of Bipolar Depression Unknown status NCT01583023 Phase 4 Bupropion
7 Assessment and Follow Up Study of Children and Adolescent With Bipolar Disorder Unknown status NCT01000402 Phase 4 Psychopharmacotherapy
8 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression. Unknown status NCT00335205 Phase 4 ropinirole
9 Clinical Psychopharmacology Division Institute of Mental Health, Peking University Unknown status NCT03148535 Phase 4 Lithium Carbonate;lithium carbonate combined with SSRI antidepressant treatment
10 A Randomized Open-label Active-controlled Study to Evaluate the Efficacy and Safety of Utapine Versus Seroquel in Patients With Bipolar Mania Unknown status NCT01043679 Phase 4 Utapine;Seroquel
11 Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
12 Open Label Prophylaxis Study of Lithium Plus Extended- Release Carbamazepine (Equetro®) Combination for Rapid Cycling Bipolar Disorder Unknown status NCT00325286 Phase 4 Lithium Plus Extended- Release Carbamazepine
13 Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs Unknown status NCT01182012 Phase 4
14 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients. Unknown status NCT01246310 Phase 4
15 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
16 Phase 3 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study Unknown status NCT00426946 Phase 4 Reboxetine
17 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
18 A Randomized, Sham Controlled, Crossover Trial of rTMS for Bipolar Depression Completed NCT00186758 Phase 4
19 Comparison of Propofol Target-Controlled Infusion Anesthesia and Bolus Injection in Electroconvulsive Therapy: A Randomized Controlled Trial Completed NCT03863925 Phase 4
20 Lamictal for Use in Treatment of Bipolar Disorder In Adults. A Practical Clinical Assessment of Tolerability and Clinical Effectiveness. Completed NCT00067938 Phase 4 lamotrigine
21 An Open-Label Extension Study to Assess the Safety of Lamotrigine in Subjects With Bipolar Disorder, Who Are in Remission Following a Manic/Hypomanic Index Episode or a Depressive Index Episode. Completed NCT00360126 Phase 4 lamotrigine
22 Lamictal As Add on Treatment in Mixed States of Bipolar Disorder Completed NCT00223509 Phase 4 Lamotrigine
23 Multi-center, Double-blind, Randomized, Comparative Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify and Depakote in 24-week Treatment of Mania in Patients With Bipolar Disorder Remitted After 6-week Treatment With Abilify and Depakote Completed NCT00545675 Phase 4 Abilify(aripiprazole);Depakote (divalproate)
24 Multi-center, Single Arm, Open Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify With Depakote in the 6-week Treatment of Acute Mania in Patients With Bipolar Disorder Completed NCT00545142 Phase 4 Abilify(Aripiprazole);Depakote(Divalproate)
25 Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder Completed NCT00050206 Phase 4 Olanzapine;Placebo
26 A 52-week, Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder Completed NCT00139594 Phase 4 licarbazepine
27 Adjunctive Ziprasidone in Overweight and Obese Patients With Bipolar Disorder Completed NCT00472641 Phase 4 Ziprasidone/Geodon
28 Quetiapine for Bipolar Disorder and Alcohol Dependence Completed NCT00457197 Phase 4 Placebo;Quetiapine
29 A Randomized, Double-Blind, Placebo Controlled Study Of Quetiapine SR (QTP) As Adjunctive Treatment In Mixed States (MS) Of Bipolar Disorder Completed NCT01195363 Phase 4 quetiapine SR;quetiapine sr placebo
30 Aripiprazole in Late Life Bipolar Disorder Completed NCT00194038 Phase 4 Aripiprazole
31 A Randomized, Double-blind, Placebo-controlled Study of the Efficacy of Ropinirole in the Treatment of Depression in Bipolar Disorder Completed NCT00314821 Phase 4 ropinirole
32 Cognitive Enhancement in Bipolar Disorder Completed NCT00597896 Phase 4 pramipexole
33 Memantine and Cognitive Dysfunction in Bipolar Disorder Completed NCT00586066 Phase 4 Memantine;Placebo
34 Olanzapine/Fluoxetine Combination Versus Lamotrigine in the Treatment of Bipolar I Depression Completed NCT00485771 Phase 4 Olanzapine;Fluoxetine;Lamotrigine
35 Gulf Evaluation of VAlproate (Depakine Chrono) in maNia Study Completed NCT00477373 Phase 4 depakine chrono
36 Olanzapine Plus Carbamazepine Versus Carbamazepine Alone in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder Completed NCT00190892 Phase 4 olanzapine;carbamazepine
37 Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder, Manic or Mixed Completed NCT00034580 Phase 4 olanzapine;risperidone
38 Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder Completed NCT00572117 Phase 4 Topiramate
39 Tranylcypromine Treatment of Bipolar Depression Completed NCT01430455 Phase 4 Tranylcypromine
40 Depakote ER Therapy for Mania Comorbid With Substance Abuse Completed NCT00208195 Phase 4 Divalproex ER
41 A Phase IV STudy of the Effectiveness of Quetiapine Extended Release 600mg Once a Day to Control the Symptoms of Manic Phase of Bipolar Disorder. Completed NCT00521365 Phase 4 Quetiapine 600mg
42 A Double-Blind, Randomized, Placebo-Controlled Trial of Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Euthymic Bipolar Disorder. Completed NCT00552760 Phase 4 Ramelteon;Placebo
43 A Double Blind, Randomized, Placebo Controlled Trial of Aripiprazole Plus Valproate in the Short-Term and Long-Term Treatment of Bipolar Disorder Completed NCT00484471 Phase 4 aripiprazole;valproate;placebo
44 A Phase 4 Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder Completed NCT00195845 Phase 4 Galantamine;Placebos
45 Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated With Bipolar I Disorder Completed NCT00094549 Phase 4 olanzapine;divalproex sodium;placebo
46 A Double-Blind, Placebo-Controlled Trial of Lamotrigine In Individuals With Bipolar Disorder and Comorbid Alcohol Dependence Completed NCT01015586 Phase 4 Lamotrigine;Placebo
47 Comparative Effectiveness of a Second Generation Antipsychotic Mood Stabilizer And a Classic Mood Stabilizer for Bipolar Disorder Completed NCT01331304 Phase 4 Lithium;Quetiapine
48 Phase 4 Study: Double-blind Placebo-controlled Trial of Depakote-ER for Depressive and Anxiety Symptoms in Non-refractory Bipolar Depression Completed NCT00226343 Phase 4 Depakote-ER
49 Bipolar Depression Assessment Study on Tx Response Completed NCT00191399 Phase 4 Olanzapine;Fluoxetine
50 A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression Completed NCT00363337 Phase 4 aripiprazole

Search NIH Clinical Center for Major Affective Disorder 8

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Carbamazepine
Clonazepam
Clozapine
CLOZAPINE (CARACO)
CLOZAPINE (CLOZARIL)
CLOZAPINE (IVAX)
CLOZAPINE (TEVA)
CLOZAPINE (VERSACLOZ)
Divalproex Sodium
Fazaclo
gabapentin
gabapentin enacarbil
lamotrigine
Lithium
Lithium Aspartate
Lithium Carbonate
lithium citrate
Mylan brand of clozapine
olanzapine
quetiapine
Quetiapine fumarate
Risperidone
Sodium Valproate
tiagabine
Tiagabine hydrochloride
topiramate
UDL brand of clozapine
Valproic Acid

Genetic Tests for Major Affective Disorder 8

Anatomical Context for Major Affective Disorder 8

MalaCards organs/tissues related to Major Affective Disorder 8:

41
Brain, Cortex, Testes, Prefrontal Cortex, Amygdala, Thyroid, Cingulate Cortex

Publications for Major Affective Disorder 8

Articles related to Major Affective Disorder 8:

(show top 50) (show all 24359)
# Title Authors PMID Year
1
Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. 38 8
18711365 2008
2
Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics in the anterior cingulate cortex during a working memory task. 38
30558824 2019
3
Upregulation of the nitrosylome in bipolar disorder type 1 (BP1) and major depression, but not BP2: Increased IgM antibodies to nitrosylated conjugates are associated with indicants of leaky gut. 38
31323278 2019
4
Glutamate receptor metabotropic 7 (GRM7) gene polymorphisms in mood disorders and attention deficit hyperactive disorder. 38
31170425 2019
5
Quetiapine induces myocardial necroptotic cell death through bidirectional regulation of cannabinoid receptors. 38
31220554 2019
6
Electronic Ecological Momentary Assessment (EMA) in youth with bipolar disorder: Demographic and clinical predictors of electronic EMA adherence. 38
31176107 2019
7
Daytime light exposure in daily life and depressive symptoms in bipolar disorder: A cross-sectional analysis in the APPLE cohort. 38
31247358 2019
8
Decreased need for sleep as an endophenotype of bipolar disorder: an actigraphy study. 38
31257931 2019
9
Switching winter and summer photoperiods in an animal model of bipolar disorder. 38
30787426 2019
10
Cognitive variability in bipolar I disorder: A cluster-analytic approach informed by resting-state data. 38
30914304 2019
11
The Psychometric Properties of the Kessler Psychological Distress Scale (K6) in an Epidemiological Sample of Canadian Youth. 38
30602296 2019
12
The Dutch Bipolar Offspring Study: Cognitive Development and Psychopathology. 38
30887148 2019
13
How Well Does the DSM-5 Capture Schizoaffective Disorder? 38
31181975 2019
14
[Chronic metabolic and renal disorders related to lithium salts treatment]. 38
30827493 2019
15
MRI acoustic noise-modulated computer animations for patient distraction and entertainment with application in pediatric psychiatric patients. 38
31078614 2019
16
Antenatal caregiving representations among expectant mothers with severe mental illness: a cross-sectional study. 38
30767656 2019
17
The evidence for physical activity in the management of major mental illnesses: a concise overview to inform busy clinicians' practice and guide policy. 38
31145143 2019
18
Identification by nano-LC-MS/MS of NT5DC2 as a protein binding to tyrosine hydroxylase: Down-regulation of NT5DC2 by siRNA increases catecholamine synthesis in PC12D cells. 38
31279527 2019
19
Development of a Novel Staging Model for Affective Disorders Using Partial Least Squares Bootstrapping: Effects of Lipid-Associated Antioxidant Defenses and Neuro-Oxidative Stress. 38
30911933 2019
20
Microarray analysis of gene expression in the diacylglycerol kinase η knockout mouse brain. 38
31297456 2019
21
Association of genetic variants at 22q11.2 chromosomal region with cognitive performance in Japanese patients with schizophrenia. 38
31193788 2019
22
Current Understanding of the Role of Neuronal Calcium Sensor 1 in Neurological Disorders. 38
30719643 2019
23
A pyruvate dehydrogenase complex disorder hypothesis for bipolar disorder. 38
31383331 2019
24
Identifying the Complexity of Diagnosing Bipolar Disorder: A Focused Ethnography. 38
31246151 2019
25
Habenula deep brain stimulation for refractory bipolar disorder. 38
31103455 2019
26
Safety considerations in the psychopharmacology of pediatric bipolar disorder. 38
31242784 2019
27
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. 38
31285147 2019
28
Abnormalities of Alpha Activity in Frontocentral Region of the Brain as a Biomarker to Diagnose Adolescents With Bipolar Disorder. 38
30642197 2019
29
Increased plasma levels of high mobility group box 1 protein in patients with bipolar disorder: A pilot study. 38
31203140 2019
30
Differential effect on myelination through abolition of activity-dependent synaptic vesicle release or reduction of overall electrical activity of selected cortical projections in the mouse. 38
30901089 2019
31
Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies. 38
30809807 2019
32
Immunity and mental illness: findings from a Danish population-based immunogenetic study of seven psychiatric and neurodevelopmental disorders. 38
30976114 2019
33
Integrating digital phenotyping in clinical characterization of individuals with mood disorders. 38
31330197 2019
34
Unmet Needs of People with Serious Mental Illness: Perspectives from Certified Peer Specialists. 38
31154551 2019
35
Neuroendocrine abnormalities associated with untreated first episode patients with major depressive disorder and bipolar disorder. 38
31125758 2019
36
A linkage and exome study implicates rare variants of KANK4 and CAP2 in bipolar disorder in a multiplex family. 38
31400178 2019
37
Bipolar Disorder and Its Comorbidities: How to Treat Since the Gold Standard for One Disease Can Worsen the Other? 38
31429219 2019
38
Progression of the functional deficit in a group of patients with bipolar disorder: a cluster analysis based on longitudinal data. 38
31422453 2019
39
A case of bipolar disorder onset with subsequent catatonia in a 14-year-old boy treated successfully with electroconvulsive therapy. 38
31430220 2019
40
Neutrophil/lymphocyte ratio, monocyte/lymphocyte ratio, and mean platelet volume as systemic inflammatory markers in different states of bipolar disorder. 38
31304832 2019
41
TP53 Polymorphism Contributes to the Susceptibility to Bipolar Disorder but Not to Schizophrenia in the Chinese Han Population. 38
31055723 2019
42
Widespread white matter microstructural abnormalities in bipolar disorder: evidence from mega- and meta-analyses across 3033 individuals. 38
31434102 2019
43
Current understandings of the trajectory and emerging correlates of cognitive impairment in bipolar disorder: an overview of evidence. 38
31408230 2019
44
Neurons and glial cells in bipolar disorder: A systematic review of postmortem brain studies of cell number and size. 38
31163205 2019
45
Predicting Bipolar Disorder Risk Factors in Distressed Young Adults From Patterns of Brain Activation to Reward: A Machine Learning Approach. 38
31201147 2019
46
Baseline and follow-up activity and functional connectivity in reward neural circuitries in offspring at risk for bipolar disorder. 38
30755725 2019
47
Behavior of self-inflicted violence in patients with bipolar disorder: A systematic review protocol. 38
31415415 2019
48
Transcriptomic abnormalities in peripheral blood in bipolar disorder, and discrimination of the major psychoses. 38
31391148 2019
49
Screening for Bipolar Disorder and Finding Borderline Personality Disorder: A Replication and Extension. 38
30036171 2019
50
Classification of Unmedicated Bipolar Disorder Using Whole-Brain Functional Activity and Connectivity: A Radiomics Analysis. 38
31408101 2019

Variations for Major Affective Disorder 8

Expression for Major Affective Disorder 8

Search GEO for disease gene expression data for Major Affective Disorder 8.

Pathways for Major Affective Disorder 8

GO Terms for Major Affective Disorder 8

Sources for Major Affective Disorder 8

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....